Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.
about
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacksAnticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutterAnticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attackProtocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN893Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-AnalysisPreventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgeryEfficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysisManagement of anticoagulant therapy for patients with prosthetic heart valves or atrial fibrillationSystematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillationLong term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation.Case report of paroxysmal atrial fibrillation and anticoagulation.My health: whose responsibility? Low-dose aspirin and older peopleCost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillationUsing anticoagulation or aspirin to prevent stroke. Research was methodologically flawed.Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.Treating individuals according to evidence: why do primary care practitioners do what they do?Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation.Venous thrombosis and anticoagulant therapy.The oral anticoagulant saga: past, present, and future.Prevention of cardioembolic stroke.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants.Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect.Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.Advancement in antithrombotics for stroke prevention in atrial fibrillation.Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness.Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial FibrillationComparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.Anticoagulation in nonvalvular atrial fibrillation.The business case for quality improvement: oral anticoagulation for atrial fibrillation.Novel oral anticoagulants to prevent stroke in atrial fibrillation.Stroke prevention in atrial fibrillation patients.Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy.Recent advances in oral anticoagulation for atrial fibrillation.Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves.
P2860
Q24244298-B34D2A22-66CE-4357-8295-CE971B7D5FC3Q24245613-CB2E37F1-A1DB-4D09-BC67-942C8F74E620Q24245863-41DEFC83-89C4-4EE9-890C-5E77ED1194E4Q24801915-1AEF6058-5E78-40FF-934E-BD2051153AF4Q26777365-99E144F2-4C7B-424C-A372-C294BF9B9ADBQ26801820-FACB154F-12D4-4C81-A48F-4D8E2CE610DCQ28081598-C38BC6DB-CACB-41EA-9BE6-146C5DB5A011Q28167261-759E4993-88E9-424C-BE29-CC9D9A805885Q28175307-7D6AA7EC-5A4C-41C7-8934-82548D4DA550Q28187842-D173790E-2951-43A5-AD10-C68002BFE6B2Q28194085-0F72FE9B-6447-44FB-8349-FDC70F78BAECQ28201631-44AB70FE-0A48-4E2F-A71E-C95A753AC16FQ28484289-A5A989E3-D1B7-4E39-8C13-E9B140ACE530Q33800650-ED95DCBA-ABBF-44A0-A28A-F5C5554FF65EQ33876319-443B0DE6-6985-45C3-B562-8510F4C239DAQ33891646-D710DD82-06F0-492D-B9E8-A415CD01FB80Q34021780-B4967BB4-2F99-4045-AE39-CBCAFD81DD71Q34202452-2BFE014A-0B10-4609-A19D-36C065DDDB38Q34233473-A31C4008-B755-44DA-8251-EA74002323B1Q34351113-45DF1AC0-6F62-4EC5-A2BC-BA49DC307B6FQ34430437-0085C957-1FB2-42D9-B1C7-67A0F49F7624Q35648111-6F750796-94F7-43AA-B59D-095305BE4988Q35752573-F847F462-7663-4F2D-A30D-A20C41F32587Q35752603-5EC7E1C8-FDC6-4259-950D-0DA3DF590EDCQ35878355-3D0503B2-CE8F-4CCD-AA06-7761296B7136Q35938914-3BADF9CC-92CF-4AE4-AB87-5D08B454E09FQ36112764-C5C57848-B160-4397-BF86-B46E97CCA085Q37015495-1A007A7B-B3AE-4ACC-876E-F9170FDBA858Q37107710-2EAEC58D-4D5A-44BE-8325-956C92DCE639Q37143256-5566B397-B163-4AE3-AC4C-9310578C96A7Q37329482-8C67B2FE-BAA3-466F-AD5F-54716A979C49Q37495942-9FBC64E7-38B3-44D6-85EB-25434DC1FBF2Q37528205-175AD21D-06A6-466D-9A70-AC237781152CQ37608499-A203E54F-A017-4028-8BA7-DF2EA018E960Q37666333-EF8696E4-4ED4-42CD-8144-22DF9AAF60AFQ37697501-F395341E-F58C-440E-B676-3EDEE52FFF49Q37780750-3E0232E8-CA2D-4C9C-B34B-280778D898AAQ37781101-1CB40FF8-CF6A-4D6A-895F-3999A7F88198Q37802084-ADF86006-C508-4FCB-B41C-59CC17DF2969Q37990454-C93BF7F7-E8A8-400C-845A-3C62D001764B
P2860
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Primary prevention of arterial ...... ties of coumarin with aspirin.
@ast
Primary prevention of arterial ...... ties of coumarin with aspirin.
@en
type
label
Primary prevention of arterial ...... ties of coumarin with aspirin.
@ast
Primary prevention of arterial ...... ties of coumarin with aspirin.
@en
prefLabel
Primary prevention of arterial ...... ties of coumarin with aspirin.
@ast
Primary prevention of arterial ...... ties of coumarin with aspirin.
@en
P2093
P2860
P921
P356
P1433
P1476
Primary prevention of arterial ...... ties of coumarin with aspirin.
@en
P2093
B S Hellemons
H J Schouten
J A Knottnerus
J W van Ree
M Langenberg
P2860
P304
P356
10.1136/BMJ.319.7215.958
P407
P577
1999-10-01T00:00:00Z